News & Updates

Maintenance monotherapy with olaparib appears safe and effective in Asian patients with platinum-sensitive relapsed (PSR) ovarian cancer, regardless of their BRCA status, as shown in the results of the phase III, open-label, single-arm L-MOCA study.

Physician-reported measures on responses to tofacitinib and adalimumab treatments are higher than those reported by patients with rheumatoid arthritis (RA), according to a post hoc analysis of data from phase III and phase IIIb/IV trials.

The prevalence of obstructive sleep apnoea (OSA) is similar between resistant and refractory hypertensive patients, a study has shown. However, those with refractory hypertension are usually younger and have a better sleep pattern.

In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

Catheter-directed thrombolysis (CDT) is superior to systemic anticoagulation (SA) for the treatment of submassive pulmonary embolism (sPE), leading to better mortality rates without additional safety signals, a recent meta-analysis has found.

Long-term overall survival (OS) in patients with metastatic breast cancer (MBC) may be influenced by diabetes status, according to a retrospective study presented at ENDO 2022.